Skip to content

Clinical trials

Heart Failure trials in Germany

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Heart Failure Country / region: Germany Clear all

532 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20012
20023
200311
200411
200510
200610
200725
200827
200921
201018
201128
201213
201329
201434
201521
201625
201740
201826
201922
202023
202115
202213
202323
202429
202525
202619

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed299
Recruiting78
Terminated63
Unknown status43
Active, not recruiting28
Not yet recruiting9
Withdrawn8
Suspended3
No longer available1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Biotronik SE & Co. KG26
Medtronic Cardiac Rhythm and Heart Failure26
Bayer25
Novartis Pharmaceuticals23
Abbott Medical Devices20
Boston Scientific Corporation16
Charite University, Berlin, Germany16
AstraZeneca15
Heart and Diabetes Center North-Rhine Westfalia12
German Heart Institute10

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Heart Failure532
Cardiovascular Diseases33
Atrial Fibrillation29
Heart Diseases29
Cardiomyopathies25
Arrhythmias, Cardiac15
Renal Insufficiency, Chronic15
Diabetes Mellitus, Type 214
Myocardial Infarction14
Sleep Apnea Syndromes14

Trials

Showing 26 to 50 of 532. Each trial links to its page on Pharma Observatory.

432 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.